<DOC>
	<DOCNO>NCT01454089</DOCNO>
	<brief_summary>The primary objective study ascertain whether evidence longer survival relative control arm three comparison : 600 mg OGX-427 Arm control Arm ; 1000 mg OGX-427 Arm control Arm ; pool 600 mg 1000 mg OGX-427 Arms control Arm .</brief_summary>
	<brief_title>A Phase 2 Study Comparing Chemotherapy Combination With OGX-427 Placebo Patients With Bladder Cancer</brief_title>
	<detailed_description>Following 3 loading dos , participant receive chemotherapy study drug 21-day cycle Treatment Period ( Chemotherapy Period ) disease progression , completion 6 cycle , toxicity voluntary participant withdrawal . Participants document disease progression complete minimum four cycle chemotherapy continue receive weekly Study Drug maintenance therapy Maintenance Period disease progression participant fulfill one reason withdrawal protocol treatment , unless discontinue protocol treatment unacceptable toxicity relate study drug . All participant End Treatment ( EOT ) visit withdrawn study treatment ( chemotherapy maintenance ) . All participant follow documented disease progression . Once disease progression document , participant enter Survival Follow-up Period data collect regard cancer therapy , secondary malignancy , survival status .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Urologic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Age ≥ 18 year time consent 2 . Histologically document metastatic locally inoperable advanced transitional cell carcinoma ( TCC ) urinary tract ( bladder , urethra , ureter renal pelvis ) ( T4b , N2 , N3 M1 disease ) NOTE : Certain mixed histology predominately ( ≥ 50 % ) TCC eligible : squamous , adenocarcinoma , undifferentiated . Mixed undifferentiated histology require immunohistochemistry ( IHC ) consistent TCC origin . Mixed smallcell histology exclude 3 . Measurable disease define least one target lesion irradiate accurately measure least one dimension Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 criterion 4 . No prior systemic chemotherapy follow exception : Prior use radiosensitizing single agent therapy allow Prior neoadjuvant adjuvant chemotherapy may allow 5 . Minimum 21 day since prior major surgery radiation therapy 6 . Karnofsky performance status ≥ 70 % 7 . Required laboratory value baseline : absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9 cells/L platelet count ≥ 125 x 10^9/L calculated creatinine clearance ≥ 60 mL/minute bilirubin ≤ 1.5 x upper limit normal ( ULN ; ≤ 2.5 x ULN secondary Gilbert 's disease ) aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 3.0 x ULN 8 . If childbearing potential , willing use contraceptives 9 . Willing give write informed consent 1 . A candidate potential curative surgery radiotherapy 2 . Intravesical therapy within last 3 month 3 . Documented brain metastasis carcinomatous meningitis , treat untreated . NOTE : Brain imaging required unless patient symptom physical sign central nervous system ( CNS ) disease . 4 . Peripheral neuropathy ≥ Grade 2 5 . Known serious hypersensitivity gemcitabine , cisplatin carboplatin 6 . Current serious , uncontrolled medical condition congestive heart failure , angina , hypertension , arrhythmia , diabetes mellitus , infection , etc . condition psychiatric illness opinion investigator would make patient unacceptable protocol 7 . Cerebrovascular accident , myocardial infarction pulmonary embolus within 6 month randomization 8 . Active second malignancy ( except nonmelanomatous skin cancer ) : active secondary malignancy define current need cancer therapy high possibility ( &gt; 30 % ) recurrence study 9 . Pregnant nursing ( must negative serum urine pregnancy test within 72 hour prior randomization ) 10 . Participating concurrent clinical trial experimental drug , vaccine device . Participation observational study allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>bladder</keyword>
	<keyword>urinary tract</keyword>
	<keyword>transitional cell carcinoma</keyword>
	<keyword>metastatic bladder cancer</keyword>
	<keyword>chemotherapy</keyword>
</DOC>